Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
- Acronyms NIVOTHYM
- 25 Apr 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 Planned initiation date changed from 1 Jan 2018 to 1 Apr 2018.
- 02 May 2017 New trial record